Company / Working Capital
Kura Oncology, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$591.7M
FY2025
5-year range
$397.2M / $666.1M
FY2021-FY2025
Trend
-11.2%
vs FY2024
Sector context
#77 of 213
Health Care
What the data says
At $592M, Kura Oncology, Inc.'s working capital ranks #77 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $63M in FY2016 to $666M in FY2024.
Based on SEC 10-K filings.
$592M in FY2025 with a 5-year CAGR of -0.6%.
Improved from $397M to $592M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +11.9%
- 5-Year CAGR
- -0.6%
- 10-Year CAGR
- -
Sector benchmark
#77 of 213 in Health CareTop 36% of 213This company $591.7M Sector average $934.6M
▼
-36.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.6%, indicating a declining trend.
- In FY2025, working capital decreased 11.2% year-over-year.
- Ranks #77 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $591.7M | -11.2% |
| FY2024 | $666.1M | +67.7% |
| FY2023 | $397.2M | -6.0% |
| FY2022 | $422.4M | -15.5% |
| FY2021 | $499.8M | -18.2% |
| FY2020 | $611.3M | +172.8% |
| FY2019 | $224.0M | +33.7% |
| FY2018 | $167.6M | +98.1% |
| FY2017 | $84.6M | +33.5% |
| FY2016 | $63.4M | -22.6% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026